Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

NCT03397888 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.

NCT NCT03397888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03397888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
Lead sponsor
Portola Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2017
Completion date
January 16, 2018
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic impairment